AXL Kinase Inhibitor - Pipeline Insight, 2022

“AXL Kinase Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in AXL Kinase Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

AXL Kinase Inhibitor Understanding

AXL Kinase Inhibitor: Overview

Axl receptor tyrosine Kinase is a member of the tyrosine‑protein Kinase receptor Tyro3, Axl and proto‑oncogene tyrosine‑protein Kinase Mer family of receptor tyrosine Kinases. AXL is a member of a complex signaling network that is involved in the control of cell proliferation and differentiation. AXL is widely expressed in healthy tissues, where it plays a variety of roles, including clearing apoptotic material, regulating cell survival, maintaining vascular integrity, and hematopoiesis. AXL has emerged as a novel biomarker due to its role in biological processes and tumorigenesis. Because of the pleiotropic role of AXL in tumor pathophysiology and drug resistance, AXL represents a promising therapeutic target in the management of cancer. AXL inhibitors have been shown to potentiate tumor cell apoptosis and suppress migration and invasion. Targeting AXL enhances the therapeutic efficacy of chemotherapy and other small-molecule inhibitors, such as VEGF, EGFR, PI3K, PARP, and HER2 inhibitors.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence AXL Kinase Inhibitor R&D. The therapies under development are focused on novel approaches for AXL Kinase Inhibitor.

AXL Kinase Inhibitor Emerging Drugs Chapters

This segment of the AXL Kinase Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

AXL Kinase Inhibitor Emerging Drugs
• Bemcentinib: BerGenBio / Rigel Pharmaceuticals

Bemcentinib (BGB324) is a potent, selective and orally bioavailable AXL inhibitor and a potential future cornerstone to therapy for aggressive diseases, including immune-evasive, therapy resistant cancers, fibrosis and viral infection. The drug is in phase II program, focused on establishing proof of concept that bemcentinib may reverse and prevent resistance to immune, targeted and chemotherapy.
• Sitravatinib: Mirati Therapeutics

Sitravatinib is an oral, potent, spectrum-selective RTK inhibitor. It inhibits several closely related RTKs, including the TAM family (TYRO3, AXL and MER), VEGFR2 and KIT. This inhibition weakens the cancer’s defenses in the tumor microenvironment.

Further product details are provided in the report……..

AXL Kinase Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different AXL Kinase Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on AXL Kinase Inhibitor

There are approx. 15+ key companies which are developing the AXL Kinase Inhibitor. The companies which have their AXL Kinase Inhibitor drug candidates in the most advanced stage, i.e. Phase III include, Mirati Therapeutics.
• Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

AXL Kinase Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

AXL Kinase Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses AXL Kinase Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging AXL Kinase Inhibitor drugs.

AXL Kinase Inhibitor Report Insights
• AXL Kinase Inhibitor Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

AXL Kinase Inhibitor Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:
• How many companies are developing AXL Kinase Inhibitor drugs?
• How many AXL Kinase Inhibitor drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for AXL Kinase Inhibitor?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the AXL Kinase Inhibitor therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for AXL Kinase Inhibitor and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• BerGenBio
• Rigel Pharmaceuticals
• Mirati Therapeutics
• Ipsen
• SignalChem Lifesciences
• Arcus Biosciences
• Symphogen
• Qurient Co
• Daiichi Sankyo Company
• Aravive
• Exelixis

Key Products
• Bemcentinib
• Sitravatinib
• Cabozantinib
• Research programme: TAM inhibitors
• Research programme: AXL receptor tyrosine kinase inhibitors
• Sym 028
• Q-702
• AB 329
• Aravive S6
• XL092